Advances in Insulin and GLP-1 Therapies

Advances in insulin therapies and glucagon-like peptide-1 (GLP-1) agonists have revolutionized the treatment of diabetes. This session will focus on the latest innovations in insulin formulations, including ultra-rapid insulins and long-acting insulins that offer improved glucose control with fewer injections. Experts will also discuss the role of GLP-1 agonists in managing type 2 diabetes and obesity, highlighting their mechanisms of action and clinical benefits.

The track will examine the current clinical guidelines for insulin and GLP-1 therapy use, as well as emerging treatments and combination therapies that offer enhanced efficacy and safety profiles. Attendees will learn about ongoing clinical trials and the potential for these therapies to further improve the management of diabetes and related comorbidities.

    Related Conference of Advances in Insulin and GLP-1 Therapies

    May 08-09, 2025

    5th European Endocrinology and Diabetes Congress

    Madrid, Spain
    May 19-20, 2025

    6th World Summit on Diabetes

    Rome, Italy
    June 04-05, 2025

    4th World Congress on Diabetes and Pediatric Endocrinology

    Edinburgh, Scotland
    July 29-30, 2025

    15th World Congress on Endocrinology and Diabetes

    Paris, France
    September 08-09, 2025

    3rd World congress and Expo on Diabetes

    Frankfurt, Germany
    October 30-31, 2025

    5th Annual Summit on Diabetes and Endocrinology

    Paris, France
    November 06-07, 2025

    8th Annual Meeting on Diabetes and Endocrinology

    Dubai, UAE
    November 20-21, 2025

    21st World Congress on Endocrinology & Diabetes

    Paris, France
    March 26-27, 2026

    7th Global summit on Diabetes and Endocrinology

    Amsterdam, Netherlands

    Advances in Insulin and GLP-1 Therapies Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in